Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1173 Results

Title
Intervention Indication Therapeutic Area Year Actions
Selinexor in addition to bortezomib and low-dose dexamethasone for relapsed or refractory multiple myeloma Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Selinexor (KPT-330; Xpovio) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2020 View  |  Download
Selinexor in combination with low-dose dexamethasone for penta-refractory multiple myeloma Dexamethasone (dexamethasone sodium metasulfobenzoate) , Selinexor (KPT-330; Xpovio) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Selonsertib for Non-alcoholic Steatohepatitis (NASH) Selonsertib (GS-4997) Non-alcoholic steatohepatitis (NASH) Hepatology 2018 View  |  Download
Selpercatinib for advanced thyroid cancer with RET alterations Selpercatinib (LOXO-292; LY3527723) Medullary thyroid cancer (MTC) , Thyroid cancer Head and Neck Cancer , Oncology 2019 View  |  Download
Selpercatinib for metastatic RET fusion-positive non-small cell lung cancer Selpercatinib (LOXO-292; LY3527723) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2019 View  |  Download
Selpercatinib for previously untreated advanced RET fusion-positive non-small cell lung cancer Selpercatinib (LOXO-292; LY3527723) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Selpercatinib for previously untreated advanced RET-fusion positive thyroid cancer Selpercatinib (LOXO-292; LY3527723) Thyroid cancer Oncology 2022 View  |  Download
Selpercatinib for previously untreated medullary thyroid cancer with RET mutation in patients ages 12 and older Selpercatinib (LOXO-292; LY3527723) Medullary thyroid cancer (MTC) Head and Neck Cancer 2022 View  |  Download
Selpercatinib for treating advanced solid tumours with RET gene fusion in people aged 12 years and older Selpercatinib (LOXO-292; LY3527723) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Selumetinib for neurofibromatosis type 1 Selumetinib (AZD6244; ARRY-142886) Neurofibromatosis Neurology 2019 View  |  Download
1 2 94 95 96 97 98 117 118
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications